Regencell Bioscience Holdings Limited Ordinary Shares (RGC)

Price$28.10

Favorite Metrics

Price vs S&P 500 (26W)61.81%

Price vs S&P 500 (4W)-4.74%

Market Capitalization$14.18B

All Metrics

Book Value / Share (Quarterly)$0.01

P/TBV (Annual)12.88x

Indicated Dividend (Annual)$0.00

Price vs S&P 500 (YTD)32.39%

EPS (TTM)$-0.01

10-Day Avg Trading Volume0.11M

EPS Excl Extra (TTM)$-0.01

EPS (Annual)$-0.01

ROI (Annual)-73.75%

Cash / Share (Quarterly)$0.01

ROA (Last FY)-62.27%

EBITD / Share (TTM)$-0.01

Cash Flow / Share (Annual)$-0.01

P/B Ratio2916.92x

P/B Ratio (Quarterly)1733.67x

Net Income / Employee (Annual)$-0

ROA (TTM)-54.16%

EPS Incl Extra (Annual)$-0.01

Current Ratio (Annual)7.39x

Quick Ratio (Quarterly)7.38x

3-Month Avg Trading Volume0.36M

52-Week Price Return3881.94%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$1.31

52-Week High$83.60

EPS Excl Extra (Annual)$-0.01

CapEx CAGR (5Y)4.94%

26-Week Price Return70.55%

Quick Ratio (Annual)7.38x

13-Week Price Return-18.48%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)7.39x

Enterprise Value$14,174.577

Revenue / Employee (Annual)$0

Cash / Share (Annual)$0.01

3-Month Return Std Dev150.55%

Net Income / Employee (TTM)$-0

ROE (Last FY)-73.75%

EPS Basic Excl Extra (Annual)$-0.01

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.01

ROI (TTM)-61.90%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.92

Price vs S&P 500 (52W)3846.85%

Year-to-Date Return36.52%

5-Day Price Return-11.07%

EPS Normalized (Annual)$-0.01

ROA (5Y Avg)-119.63%

Month-to-Date Return12.74%

EBITD / Share (Annual)$-0.01

EPS Basic Excl Extra (TTM)$-0.01

P/TBV (Quarterly)9.08x

P/B Ratio (Annual)1733.67x

Book Value / Share (Annual)$0.01

Price vs S&P 500 (13W)-21.35%

Beta2.08x

Revenue / Share (TTM)$0.00

ROE (TTM)-61.90%

52-Week Low$0.70

About

Regencell Bioscience Holdings Ltd develops and commercializes traditional Chinese medicine (TCM) treatments for neurocognitive and immune-related disorders. The company's pipeline targets attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and infectious diseases affecting immune function.